摘要
目的:探讨用氟桂利嗪、倍他司汀联合头痛宁治疗偏头痛性眩晕的效果.方法:选取2017年1月至12月期间三河市燕郊人民医院神经内科收治的131例偏头痛性眩晕患者作为研究对象.按照随机数表法将这些患者分为观察组(n=66)和对照组(n=65).为观察组患者采用氟桂利嗪、倍他司汀联合头痛宁进行治疗,为对照组患者采用氟桂利嗪和倍他司汀进行治疗.然后比较两组患者用药的安全性、眩晕残障程度评定量表(DHI)的评分及病情的复发率.结果:在治疗期间,两组患者不良反应的发生率相比,P>0.05.治疗后,观察组患者病情的复发率、DHI的评分均低于对照组患者,P<0.05.结论:用氟桂利嗪、倍他司汀联合头痛宁治疗偏头痛性眩晕的效果较为理想,可有效地降低该病患者病情的复发率及DHI的评分,且安全性较高.
objective:to investigate the effect of flunarizine and betastatin combined with toungning in the treatment of migraine induced vertigo.Methods:131 patients with migraine vertigo admitted to the department of neurology,yanjiao people’s hospital of sanhe city from January to December 2017 were selected as the research objects.These patients were divided into observation group(n=66)and control group(n=65)according to the random number table method.Patients in the observation group were treated with flunarizine,betastatin and toungine,and patients in the control group were treated with flunarizine and betastatin.The drug safety,DHI score and relapse rate were compared between the two groups.Results:during the treatment period,the incidence of adverse reactions in the two groups was P>0.05.After treatment,the relapse rate and DHI score of patients in the observation group were lower than those in the control group(P<0.05).Conclusion:the efficacy of flunarizine,betastatin combined with toungning in the treatment of migraine vertigo is relatively ideal,which can effectively reduce the recurrence rate and DHI score of patients with this disease,and is relatively safe.
作者
王芬
Wang fen(department of neurology,sanhe yanjiao people’s hospital,sanhe hebei 065201)
关键词
偏头痛性眩晕
氟桂利嗪
倍他司汀
头痛宁
migraine vertigo
Flunarizine
Betastatin
Have a headache better
